Showing results (581-590 of 739) with videos related to
Sort By:
Pageof 74
Immunity & Ageing : I & A|July 1, 2023
Immunogenicity of adjuvanted versus high-dose inactivated influenza vaccines in older adults: a randomized clinical trialKenneth E Schmader, Christine K Liu, Brendan Flannery, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemiaRoland B Walter, Ted A Gooley, Brent L Wood, et al.Cancers|January 10, 2026
DNA Damage Sensing and TP53 Function as Modulators of Sensitivity to Calicheamicin-Based Antibody-Drug Conjugates for Acute LeukemiaCamryn M Pettenger-Willey, George S Laszlo, Margery Gang, et al.Proceedings of the National Academy of Sciences of the United States of America|August 10, 2011
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutininJames R R Whittle, Ruijun Zhang, Surender Khurana, et al.Ebiomedicine|May 28, 2024
A chimeric haemagglutinin-based universal influenza virus vaccine boosts human cellular immune responses directed towards the conserved haemagglutinin stalk domain and the viral nucleoproteinCarly M Bliss, Raffael Nachbagauer, Chiara Mariottini, et al.Nano Letters|July 18, 2022
Large-Area Superconducting Nanowire Single-Photon Detectors for Operation at Wavelengths up to 7.4 μmMarco Colangelo, Alexander B Walter, Boris A Korzh, et al.International Journal of Cancer|March 7, 2014
Non-steroidal anti-inflammatory drugs and cancer risk in women: results from the Women's Health InitiativeTheodore M Brasky, Jingmin Liu, Emily White, et al.Leukemia|August 13, 2014
Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer CenterR B Walter, M Othus, A K Burnett, et al.Blood|January 18, 2013
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patientsRoland B Walter, Megan Othus, Alan K Burnett, et al.Blood|April 18, 2013
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemiaStephen H Petersdorf, Kenneth J Kopecky, Marilyn Slovak, et al.Pageof 74